Previous close | 10.17 |
Open | 10.25 |
Bid | 0.00 x 1300 |
Ask | 0.00 x 1800 |
Day's range | 10.20 - 10.91 |
52-week range | 7.61 - 19.99 |
Volume | |
Avg. volume | 4,927,146 |
Market cap | 1.997B |
Beta (5Y monthly) | 2.51 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.07 |
Earnings date | 03 Aug 2022 - 08 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 17.45 |
BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BioCryst Pharmaceuticals (NASDAQ: BCRX) stock defied the market's gravity on Wednesday by rising incrementally. Although it was a challenging day for stocks in general, with the S&P 500 index sinking by over 1%, BioCryst landed in the black thanks to some encouraging regulatory news. Before market open, BioCryst announced that the Food and Drug Administration (FDA) has granted its BCX9250 investigational drug fast-track designation.
The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.